
ESSA Pharma Investor Relations Material
Latest events

AGM 2024
ESSA Pharma

Q3 2025
13 Aug, 2025

Q2 2025
8 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ESSA Pharma Inc
Access all reports
ESSA Pharma Inc. is a clinical-stage pharmaceutical company primarily focused on the development of novel therapies for the treatment of prostate cancer. The company is pioneering the creation of a new class of drugs known as "anitens," which are designed to disrupt the androgen receptor signaling pathway, a key driver in the progression of prostate cancer. ESSA's lead clinical candidate, masofaniten (formerly known as EPI-7386), targets the N-terminal domain of the androgen receptor, aiming to offer a novel approach for patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, especially those who have developed resistance to current anti-androgen therapies. The company is headquartered in Vancouver, Canada, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
EPIX
Country
🇺🇸 United States